Updates in the Use of the mTOR Inhibitor Everolimus in Advanced Breast CancerJennifer Anderson* and Sandra Cuellar
University of Illinois at Chicago College of Pharmacy, 833 S Wood St., Chicago, IL 60612, USA
- *Corresponding Author:
- Jennifer Anderson
University of Illinois at Chicago College of Pharmacy
833 S Wood St., Chicago, IL 60612, USA
E-mail: [email protected]
Received date: March 02, 2016; Accepted date: April 05, 2016; Published date: April 12, 2016
Citation: Anderson J, Cuellar S (2016) Updates in the Use of the mTOR Inhibitor Everolimus in Advanced Breast Cancer. J Cancer Clin Trials 1:112. doi:10.4172/jcct.1000112
Copyright: © 2016 Anderson J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The inhibitors of mammalian target or rapamycin (mTOR) exhibit antitumor activity via disruption of various signaling pathways and have shown activity when used in combination with hormonal therapy in breast cancer. A review of the role of the efficacy and management of adverse effects of everolimus in combination with exemestane in advanced breast cancer was previously reported by Ng and colleagues. The purpose of this commentary is to provide an update on the efficacy and safety of everolimus in advanced breast cancer, as well as explore the prognostic role of biomarkers. Since 2012, there has been an update on the efficacy of BOLERO-2 as well as an examination of biomarkers. Additionally, everolimus has been investigated in other settings for advanced breast cancer. An update on the adverse effect profile and management of stomatitis associated with everolimus is also provided.